Moderna Partners to Develop Vaccine for Bundibugyo Ebola Strain
What’s happening
Moderna partnered with a global health coalition to develop a vaccine targeting the Bundibugyo strain of Ebola, the strain responsible for the ongoing outbreak.
Existing Ebola vaccines were developed for other strains and may not provide sufficient protection against Bundibugyo Ebola.
What’s changing / Business impact
The project expands the use of mRNA vaccine technology beyond COVID and demonstrates how quickly vaccine platforms can be adapted to emerging threats.
It also strengthens Moderna's position in infectious disease research.
Why this matters
Many people assume all Ebola viruses are identical, but there are multiple strains.
A vaccine designed for one strain may not work as effectively against another, which is why researchers are racing to create a targeted vaccine for the current outbreak.